Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CRT costs modeled

This article was originally published in The Gray Sheet

Executive Summary

Cardiac resynchronization therapy "appears to be an economically meaningful treatment strategy," according to an economic impact analysis of CRT released Sept. 2 at the European Society of Cardiology Congress in Vienna. The model, developed on behalf of the Eucomed CRT Steering Committee, shows that CRT can save about $3,600 in hospitalization costs per patient in the first year, compared to standard heart failure drug therapy. Guidant, one of the contributors to the Eucomed study, expects to release a CRT economic impact analysis based on its COMPANION trial in 2004 (1"The Gray Sheet" April 7, 2003, p. 3)...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT018958

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel